AMS Group reports ‘strong’ first half amid rumoured takeover interest September 18, 2024 In the six months to June, revenue rose by eight per cent to £68.0m, with strong growth in the firm's surgical business unit offsetting "challenges" in its Woundcare unit.
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
Fusion Antibodies: Pharma firm has ‘challenging’ year despite strong sales pipeline September 5, 2024 Pharmaceutical company Fusion Antibodies said it had a “challenging” year but has seen its sales pipeline grow. Fusion posted audited revenue of £1.14m for the year ended March 2024, a 60 per cent drop from the £2.9m it reported in 2023. The company, which specialises in antibody discovery, engineering and supply for therapeutic drugs, said [...]
Private equity groups circle UK pharmacy wholesaler September 2, 2024 HIG and Capvest have joined a line of private equity groups looking to buy the largest supplier of goods to British pharmacies, AAH Pharmaceuticals, from German private equity firm Aurelius. AAH has been put up for sale again only a few years after being bought by Aurelius in 2022, according to the Financial Times. The [...]
Curing cancer and cleaning our oceans? Here’s why I’m betting on biotech September 1, 2024 Something that can cure cancer and clean our oceans? Biotech sounds too good to be true, but some things really are just like magic, writes Andrew Craig.
AS Watson: Pharma partner Icanthera’s cash reserves soar August 27, 2024 UK-based pharmaceutical company Icanthera said its cash reserves soared over the last year as it has struck a major deal and is focusing on developing new products. The company that manufactures dermatology and oncology treatments said its cash position increased to £61,000 at 31 March 2024, up from £3,000 in the previous year. Icanthera said [...]
GSK receives US breakthrough therapy designation for lung cancer treatment August 20, 2024 Pharmaceutical group GSK has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) for a key lung cancer treatment. The breakthrough therapy designation is designed to expedite the development and review of drugs with the potential to treat a serious condition. Only treatments that are shown to offer a substantial improvement [...]
How Astrazeneca became the London Stock Exchange’s newest £200bn firm August 14, 2024 Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]
Hikma given shot in the arm by ‘excellent’ double-digit growth August 8, 2024 Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer August 6, 2024 GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.